Lobbying Relationship

Client

Kythera Biopharmaceuticals, Inc

More records

Lobbying firm

Mercury

More records

  • Pharmaceutical compounding. S. 959, Pharmaceutical Quality, Security, and Accountability Act; H. R. 3204, Drug Quality and Security Act.

Duration: to

General Issues: Health Issues

Spending: about $100,000 (But it's complicated. Here's why.)

Agencies lobbied since 2013: House of Representatives, U.S. Senate

Bills mentioned

S.959: Pharmaceutical Quality, Security, and Accountability Act

Sponsor: Tom Harkin (D-Iowa)

H.R.3204: Drug Quality and Security Act

Sponsor: Fred Upton (R-Mich.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Ed Kutler Asst to the Speaker, House Rep. Whip
Alan Elias LA Senators Norm Colemand and Ron Johnson
Alan Elias (continued) Prof. Staff Sen. Homeland Security & Gov. Affs
Erick Mullen Spec Asst to Majority Leader Hoyer Deputy Chief of Staff to Sen. Charles E. Schumer

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q3 Report
Q2 Report
Amendment
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page